Engineering nanosystems for transdermal delivery of antihypertensive drugs

References

• Natsis M, Antza C, Doundoulakis I, Stabouli S, Kotsis V. Hypertension in obesity: novel Insights. Curr Hypertension Rev. 2020;16(1):30–36.
   PubMed Web of Science ®Google Scholar
• Oliveros E, Patel H, Kyung S, Fugar S, Goldberg A, Madan N, Williams KA. Hypertension in older adults: assessment, management, and challenges. Clin Cardiol. 2020;43(2):99–107. doi:10.1002/clc.23303.
   PubMed Web of Science ®Google Scholar
• Flack JM, Adekola B. Blood pressure and the new ACC/AHA hypertension guidelines. Trends Cardiovasc Med. 2020;30(3):160–164. doi:10.1016/j.tcm.2019.05.003.
   PubMed Web of Science ®Google Scholar
• Carey RM, Moran AE, Whelton PK. Treatment of hypertension: a review. Jama. 2022;328(18):1849–1861. doi:10.1001/jama.2022.19590.
   PubMed Web of Science ®Google Scholar
• do Vale GT, Ceron CS, Gonzaga NA, Simplicio JA, Padovan JC. Three generations of β-blockers: history, class differences and clinical applicability. Curr Hypertens Rev. 2019;15(1):22–31. doi:10.2174/1573402114666180918102735.
   PubMed Web of Science ®Google Scholar
• Sica DA. Calcium channel blocker class heterogeneity: select aspects of pharmacokinetics and pharmacodynamics. J Clin Hypertens (Greenwich). 2005;7(4 Suppl 1):21–26. doi:10.1111/j.1524-6175.2006.04482.x.
   PubMedGoogle Scholar
• Gomes C, Ferreira D, Carvalho JPF, Barreto CAV, Fernandes J, Gouveia M, Ribeiro F, Duque AS, Vieira SI. Current genetic engineering strategies for the production of antihypertensive ACEI peptides. Biotechnol Bioeng. 2020;117(8):2610–2628. doi:10.1002/bit.27373.
   PubMed Web of Science ®Google Scholar
• Pradhan A, Tiwari A, Sethi R. Azilsartan: current evidence and perspectives in management of hypertension. Int J Hypertens. 2019;2019:1824621–1824628. doi:10.1155/2019/1824621.
   PubMed Web of Science ®Google Scholar
• Blowey DL. Diuretics in the treatment of hypertension. Pediatr Nephrol. 2016;31(12):2223–2233. doi:10.1007/s00467-016-3334-4.
   PubMed Web of Science ®Google Scholar
• Azizi M, Rossignol P, Hulot JS. Emerging drug classes and their potential use in hypertension. Hypertension. 2019;74(5):1075–1083. doi:10.1161/HYPERTENSIONAHA.119.12676.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Rakugi H. Angiotensin receptor-neprilysin inhibitors: comprehensive review and implications in hypertension treatment. Hypertens Res. 2021;44(10):1239–1250. doi:10.1038/s41440-021-00706-1.
   PubMed Web of Science ®Google Scholar
• Guan Y, Li X, Li H, Ren J, Tang K, Zhang C, Gu Z, Li X, Lv Q, Bian X. Sacubitril/valsartan in heart failure with hypertension patients: real-world experiences on different ages, drug doses, and renal functions. High Blood Press Cardiovasc Prev. 2023;30(6):561–572. doi:10.1007/s40292-023-00606-0.
   PubMed Web of Science ®Google Scholar
• Zuo C, Li X, Fan L, Li J, Tian D, Chen C, Li X, Lv Q. Effectiveness and safety of sacubitril/valsartan for patients with hypertension and heart failure in the real-world setting: a retrospective study in China. J Clin Pharm Ther. 2022;47(10):1539–1547. doi:10.1111/jcpt.13699.
   PubMed Web of Science ®Google Scholar
• Sharma M, Sharma R, Jain DK. Nanotechnology based approaches for enhancing oral bioavailability of poorly water soluble antihypertensive drugs. Scientifica (Cairo). 2016;2016:8525679–8525611. doi:10.1155/2016/8525679.
   PubMedGoogle Scholar
• Ita K, Ashong S. Percutaneous delivery of antihypertensive agents: advances and challenges. AAPS PharmSciTech. 2020;21(2):56. doi:10.1208/s12249-019-1583-9.
   PubMed Web of Science ®Google Scholar
• Kumar L, Utreja P. Transcending the cutaneous barrier through nanocarrier exploration for passive delivery of anti-hypertensive drugs: a critical review. Recent Pat Nanotechnol. 2020;14(3):193–209. doi:10.2174/1872210514666200519071734.
   PubMed Web of Science ®Google Scholar
• Ahad A, Al-Jenoobi FI, Al-Mohizea AM, Akhtar N, Raish M, Aqil M. Systemic delivery of β-blockers via transdermal route for hypertension. Saudi Pharm J. 2015;23(6):587–602. doi:10.1016/j.jsps.2013.12.019.
   PubMed Web of Science ®Google Scholar
• Ahad A, Al-Jenoobi FI, Al-Mohizea AM, Aqil M, Kohli K. Transdermal delivery of calcium channel blockers for hypertension. Expert Opin Drug Deliv. 2013;10(8):1137–1153. doi:10.1517/17425247.2013.783562.
   PubMed Web of Science ®Google Scholar
• Ahad A, Al-Mohizea AM, Al-Jenoobi FI, Aqil M. Transdermal delivery of angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs) and others for management of hypertension. Drug Deliv. 2016;23(2):579–590. doi:10.3109/10717544.2014.942444.
   PubMed Web of Science ®Google Scholar
• Sica DA, Grubbs R. Transdermal clonidine: therapeutic considerations. J Clin Hypertens (Greenwich). 2005;7(9):558–562. doi:10.1111/j.1524-6175.2005.04133.x.
   PubMedGoogle Scholar
• Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751–760. doi:10.1038/nnano.2007.387.
   PubMed Web of Science ®Google Scholar
• Cheng Z, Li M, Dey R, Chen Y. Nanomaterials for cancer therapy: current progress and perspectives. J Hematol Oncol. 2021;14(1):85. doi:10.1186/s13045-021-01096-0.
   PubMed Web of Science ®Google Scholar
• Shabbir M, Nagra U, Zaman M, Mahmood A, Barkat K. Lipid vesicles and nanoparticles for non-invasive topical and transdermal drug delivery. Curr Pharm Des. 2020;26(18):2149–2166. doi:10.2174/1381612826666200114090659.
   PubMed Web of Science ®Google Scholar
• Desfrançois C, Auzély R, Texier I. Lipid nanoparticles and their hydrogel composites for drug delivery: a review. Pharmaceuticals (Basel). 2018;11(4):118–142. doi:10.3390/ph11040118.
   PubMedGoogle Scholar
• Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261–1268. doi:10.1038/nbt.1504.
   PubMed Web of Science ®Google Scholar
• Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol. 2000;9(3):165–169. doi:10.1034/j.1600-0625.2000.009003165.x.
   PubMed Web of Science ®Google Scholar
• Lev-Tov H, Maibach HI. Regional variations in percutaneous absorption. J Drugs Dermatol. 2012;11(10):e48–51.
   PubMedGoogle Scholar
• Yosipovitch G, Xiong GL, Haus E, Sackett-Lundeen L, Ashkenazi I, Maibach HI. Time-dependent variations of the skin barrier function in humans: transepidermal water loss, stratum corneum hydration, skin surface pH, and skin temperature. J Invest Dermatol. 1998;110(1):20–23. doi:10.1046/j.1523-1747.1998.00069.x.
   PubMed Web of Science ®Google Scholar
• Schmidt GR, Schuna AA, Goodfriend TL. Transdermal clonidine compared with hydrochlorothiazide as monotherapy in elderly hypertensive males. J Clin Pharmacol. 1989;29(2):133–139. doi:10.1002/j.1552-4604.1989.tb03301.x.
   PubMed Web of Science ®Google Scholar
• Antoine JL, Contreras JL, Van Neste DJ. pH influence of surfactant-induced skin irritation. A non-invasive, multiparametric study with sodium laurylsulfate. Derm Beruf Umwelt. 1989;37(3):96–100.
   PubMedGoogle Scholar
• Nangia A, Andersen PH, Berner B, Maibach HI. High dissociation constants (pKa) of basic permeants are associated with in vivo skin irritation in man. Contact Dermatitis. 1996;34(4):237–242. doi:10.1111/j.1600-0536.1996.tb02192.x.
   PubMed Web of Science ®Google Scholar
• Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017;9(2):12. doi:10.3390/pharmaceutics9020012.
   PubMed Web of Science ®Google Scholar
• Guan Y, Zuo T, Chang M, Zhang F, Wei T, Shao W, Lin G. Propranolol hydrochloride-loaded liposomal gel for transdermal delivery: characterization and in vivo evaluation. Int J Pharm. 2015;487(1-2):135–141. doi:10.1016/j.ijpharm.2015.04.023.
   PubMed Web of Science ®Google Scholar
• Hussain A, Singh S, Sharma D, Webster TJ, Shafaat K, Faruk A. Elastic liposomes as novel carriers: recent advances in drug delivery. Int J Nanomedicine. 2017;12:5087–5108. doi:10.2147/IJN.S138267.
   PubMed Web of Science ®Google Scholar
• Mishra D, Garg M, Dubey V, Jain S, Jain NK. Elastic liposomes mediated transdermal delivery of an anti-hypertensive agent: propranolol hydrochloride. J Pharm Sci. 2007;96(1):145–155. doi:10.1002/jps.20737.
   PubMed Web of Science ®Google Scholar
• Manvir A, Rana AC, Seth N, Bala R. Elastic liposome mediated transdermal delivery of an anti-hypertensive agent: nifedipine. J Drug Delivery Ther. 2012;2(5):145–155. doi:10.22270/jddt.v2i5.278.
   Google Scholar
• Benson HA. Transfersomes for transdermal drug delivery. Expert Opin Drug Deliv. 2006;3(6):727–737. doi:10.1517/17425247.3.6.727.
   PubMedGoogle Scholar
• Cevc G, Blume G. Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force. Biochim Biophys Acta. 1992;1104(1):226–232. doi:10.1016/0005-2736(92)90154-e.
   PubMed Web of Science ®Google Scholar
• Cevc G, Schätzlein A, Richardsen H. Ultradeformable lipid vesicles can penetrate the skin and other semi-permeable barriers unfragmented. Evidence from double label CLSM experiments and direct size measurements. Biochim Biophys Acta. 2002;1564(1):21–30. doi:10.1016/s0005-2736(02)00401-7.
   PubMed Web of Science ®Google Scholar
• van den Bergh BA, Bouwstra JA, Junginger HE, Wertz PW. Elasticity of vesicles affects hairless mouse skin structure and permeability. J Control Release. 1999;62(3):367–379. doi:10.1016/s0168-3659(99)00168-6.
   PubMed Web of Science ®Google Scholar
• Honeywell-Nguyen PL, Wouter Groenink HW, de Graaff AM, Bouwstra JA. The in vivo transport of elastic vesicles into human skin: effects of occlusion, volume and duration of application. J Control Release. 2003;90(2):243–255. doi:10.1016/s0168-3659(03)00202-5.
   PubMed Web of Science ®Google Scholar
• Ahad A, Aqil M, Kohli K, Sultana Y, Mujeeb M, Ali A. Formulation and optimization of nanotransfersomes using experimental design technique for accentuated transdermal delivery of valsartan. Nanomedicine. 2012;8(2):237–249. doi:10.1016/j.nano.2011.06.004.
   PubMed Web of Science ®Google Scholar
• Ahad A, Aqil M, Kohli K, Sultana Y, Mujeeb M. The ameliorated longevity and pharmacokinetics of valsartan released from a gel system of ultradeformable vesicles. Artif Cells Nanomed Biotechnol. 2016;44(6):1457–1463. doi:10.3109/21691401.2015.1041638.
   PubMed Web of Science ®Google Scholar
• Ahad A, Al-Saleh AA, Al-Mohizea AM, Al-Jenoobi FI, Raish M, Yassin AEB, Alam MA. Formulation and characterization of Phospholipon 90 G and tween 80 based transfersomes for transdermal delivery of eprosartan mesylate. Pharm Dev Technol. 2018;23(8):787–793. doi:10.1080/10837450.2017.1330345.
   PubMed Web of Science ®Google Scholar
• Ahad A, Al-Saleh AA, Al-Mohizea AM, Al-Jenoobi FI, Raish M, Yassin AEB, Alam MA. Formulation and characterization of novel soft nanovesicles for enhanced transdermal delivery of eprosartan mesylate. Saudi Pharm J. 2017;25(7):1040–1046. doi:10.1016/j.jsps.2017.01.006.
   PubMed Web of Science ®Google Scholar
• Ahad A, Al-Saleh AA, Al-Mohizea AM, Al-Jenoobi FI, Raish M, Yassin AEB, Alam MA. Pharmacodynamic study of eprosartan mesylate-loaded transfersomes Carbopol(®) gel under Dermaroller(®) on rats with methyl prednisolone acetate-induced hypertension. Biomed Pharmacother. 2017;89:177–184. doi:10.1016/j.biopha.2017.01.164.
   PubMed Web of Science ®Google Scholar
• Morsi NM, Aboelwafa AA, Dawoud MH. Improved bioavailability of timolol maleate via transdermal transfersomal gel: statistical optimization, characterization, and pharmacokinetic assessment. J Adv Res. 2016;7(5):691–701. doi:10.1016/j.jare.2016.07.003.
   PubMed Web of Science ®Google Scholar
• Morsi NM, Aboelwafa AA, Dawoud MHS. Enhancement of the bioavailability of an antihypertensive drug by transdermal protransfersomal system: formulation and in vivo study. J Liposome Res. 2018;28(2):137–148. doi:10.1080/08982104.2017.1295989.
   PubMed Web of Science ®Google Scholar
• El Zaafarany GM, Awad GAS, Holayel SM, Mortada ND. Role of edge activators and surface charge in developing ultradeformable vesicles with enhanced skin delivery. Int J Pharm. 2010;397(1-2):164–172. doi:10.1016/j.ijpharm.2010.06.034.
   PubMed Web of Science ®Google Scholar
• Birkodi S, Patil AS, Masareddy R, Rajpurohit M. Fabrication, optimization, and evaluation of transdermal patch: as an alternative and effective transdermal delivery system for nebivolol HCl. Pharm Nanotechnol 2023;12(1):79–89. doi:10.2174/2211738511666230601103658.
   PubMedGoogle Scholar
• Lastra G, Syed S, Kurukulasuriya LR, Manrique C, Sowers JR. Type 2 diabetes mellitus and hypertension: an update. Endocrinol Metab Clin North Am. 2014;43(1):103–122. doi:10.1016/j.ecl.2013.09.005.
   PubMed Web of Science ®Google Scholar
• Ramkanth S, Anitha P, Gayathri R, Mohan S, Babu D. Formulation and design optimization of nano-transferosomes using pioglitazone and eprosartan mesylate for concomitant therapy against diabetes and hypertension. Eur J Pharm Sci. 2021;162:105811. doi:10.1016/j.ejps.2021.105811.
   PubMed Web of Science ®Google Scholar
• Touitou E, Dayan N, Bergelson L, Godin B, Eliaz M. Ethosomes – novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J Control Release. 2000;65(3):403–418. doi:10.1016/s0168-3659(99)00222-9.
   PubMed Web of Science ®Google Scholar
• Nainwal N, Jawla S, Singh R, Saharan VA. Transdermal applications of ethosomes - a detailed review. J Liposome Res. 2019;29(2):103–113. doi:10.1080/08982104.2018.1517160.
   PubMed Web of Science ®Google Scholar
• Ahad A, Aqil M, Kohli K, Sultana Y, Mujeeb M. Enhanced transdermal delivery of an anti-hypertensive agent via nanoethosomes: statistical optimization, characterization and pharmacokinetic assessment. Int J Pharm. 2013;443(1-2):26–38. doi:10.1016/j.ijpharm.2013.01.011.
   PubMed Web of Science ®Google Scholar
• Ahad A, Aqil M, Kohli K, Sultana Y, Mujeeb M. Nano vesicular lipid carriers of angiotensin II receptor blocker: anti-hypertensive and skin toxicity study in focus. Artif Cells Nanomed Biotechnol. 2016;44(3):1002–1007. doi:10.3109/21691401.2015.1008509.
   PubMed Web of Science ®Google Scholar
• Bhosale SS, Avachat AM. Design and development of ethosomal transdermal drug delivery system of valsartan with preclinical assessment in Wistar albino rats. J Liposome Res. 2013;23(2):119–125. doi:10.3109/08982104.2012.753457.
   PubMed Web of Science ®Google Scholar
• Nasr AM, Moftah F, Abourehab MAS, Gad S. Design, formulation, and characterization of valsartan nanoethosomes for improving their bioavailability. Pharmaceutics. 2022;14(11):2268. doi:10.3390/pharmaceutics14112268.
   PubMed Web of Science ®Google Scholar
• Ibrahim TM, Abdallah MH, El-Megrab NA, El-Nahas HM. Transdermal ethosomal gel nanocarriers; a promising strategy for enhancement of anti-hypertensive effect of carvedilol. J Liposome Res. 2019;29(3):215–228. doi:10.1080/08982104.2018.1529793.
   PubMed Web of Science ®Google Scholar
• Amarachinta PR, Sharma G, Samed N, Chettupalli AK, Alle M, Kim J-C. Central composite design for the development of carvedilol-loaded transdermal ethosomal hydrogel for extended and enhanced anti-hypertensive effect. J Nanobiotechnology. 2021;19(1):100. doi:10.1186/s12951-021-00833-4.
   PubMed Web of Science ®Google Scholar
• Salem HF, El-Menshawe SF, Khallaf RA, Rabea YK. A novel transdermal nanoethosomal gel of lercanidipine HCl for treatment of hypertension: optimization using Box-Benkhen design, in vitro and in vivo characterization. Drug Deliv Transl Res. 2020;10(1):227–240. doi:10.1007/s13346-019-00676-5.
   PubMed Web of Science ®Google Scholar
• Moideen Muthu Mohamed J, Khan BA, Rajendran V, El-Sherbiny M, Othman G, Bashir Ahmed Hussamuldin A, Hamed Al-Serwi R. Polymeric ethosomal gel loaded with nimodipine: optimisation, pharmacokinetic and histopathological analysis. Saudi Pharm J. 2022;30(11):1603–1611. doi:10.1016/j.jsps.2022.09.003.
   PubMed Web of Science ®Google Scholar
• Mishra A, Khunt D, Ghayal A, Patel C, Shah D. Formulation and optimization of ethosomes for transdermal delivery of felodipine. Res J Pharm Technol (RJPT). 2013;5:1509–1517.
   Google Scholar
• Albash R, Abdelbary AA, Refai H, El-Nabarawi MA. Use of transethosomes for enhancing the transdermal delivery of olmesartan medoxomil: in vitro, ex vivo, and in vivo evaluation. Int J Nanomedicine. 2019;14:1953–1968. doi:10.2147/IJN.S196771.
   PubMed Web of Science ®Google Scholar
• Kumar L, Utreja P. Formulation and characterization of transethosomes for enhanced transdermal delivery of propranolol hydrochloride. MNS. 2020;12(1):38–47. doi:10.2174/1876402911666190603093550.
   Google Scholar
• Babaie S, Bakhshayesh ARD, Ha JW, Hamishehkar H, Kim KH. Invasome: a novel nanocarrier for transdermal drug delivery. Nanomaterials (Basel). 2020;10(2):341–353. doi:10.3390/nano10020341.
   PubMedGoogle Scholar
• Ahad A, Aqil M, Kohli K, Sultana Y, Mujeeb M, Ali A. Interactions between novel terpenes and main components of rat and human skin: mechanistic view for transdermal delivery of propranolol hydrochloride. Curr Drug Deliv. 2011;8(2):213–224. doi:10.2174/156720111794479907.
   PubMed Web of Science ®Google Scholar
• Ahad A, Aqil M, Kohli K, Sultana Y, Mujeeb M, Ali A. Role of novel terpenes in transcutaneous permeation of valsartan: effectiveness and mechanism of action. Drug Dev Ind Pharm. 2011;37(5):583–596. doi:10.3109/03639045.2010.532219.
   PubMed Web of Science ®Google Scholar
• Kamran M, Ahad A, Aqil M, Imam SS, Sultana Y, Ali A. Design, formulation and optimization of novel soft nano-carriers for transdermal olmesartan medoxomil delivery: in vitro characterization and in vivo pharmacokinetic assessment. Int J Pharm. 2016;505(1-2):147–158. doi:10.1016/j.ijpharm.2016.03.030.
   PubMedGoogle Scholar
• Qadri GR, Ahad A, Aqil M, Imam SS, Ali A. Invasomes of isradipine for enhanced transdermal delivery against hypertension: formulation, characterization, and in vivo pharmacodynamic study. Artif Cells Nanomed Biotechnol. 2017;45(1):139–145. doi:10.3109/21691401.2016.1138486.
   PubMed Web of Science ®Google Scholar
• Ammar HO, Tadros MI, Salama NM, Ghoneim AM. Ethosome-derived invasomes as a potential transdermal delivery system for vardenafil hydrochloride: development, optimization and application of physiologically based pharmacokinetic modeling in adults and geriatrics. Int J Nanomedicine. 2020;15:5671–5685. doi:10.2147/IJN.S261764.
   PubMed Web of Science ®Google Scholar
• Marianecci C, Di Marzio L, Rinaldi F, Celia C, Paolino D, Alhaique F, Esposito S, Carafa M. 2014. Niosomes from 80s to present: the state of the art. Adv Colloid Interface Sci. 205:187–206. doi:10.1016/j.cis.2013.11.018.
   PubMed Web of Science ®Google Scholar
• Qumbar M, Ameeduzzafar, Imam SS, Ali J, Ahmad J, Ali A. Formulation and optimization of lacidipine loaded niosomal gel for transdermal delivery: in-vitro characterization and in-vivo activity. Biomed Pharmacother. 2017;93:255–266. doi:10.1016/j.biopha.2017.06.043.
   PubMed Web of Science ®Google Scholar
• Aburahma MH. Bile salts-containing vesicles: promising pharmaceutical carriers for oral delivery of poorly water-soluble drugs and peptide/protein-based therapeutics or vaccines. Drug Deliv. 2016;23(6):1847–1867. doi:10.3109/10717544.2014.976892.
   PubMed Web of Science ®Google Scholar
• Arzani G, Haeri A, Daeihamed M, Bakhtiari-Kaboutaraki H, Dadashzadeh S. Niosomal carriers enhance oral bioavailability of carvedilol: effects of bile salt-enriched vesicles and carrier surface charge. Int J Nanomed. 2015;10:4797–4813.
   PubMed Web of Science ®Google Scholar
• Albash R, El-Nabarawi MA, Refai H, Abdelbary AA. Tailoring of PEGylated bilosomes for promoting the transdermal delivery of olmesartan medoxomil: in-vitro characterization, ex-vivo permeation and in-vivo assessment. Int J Nanomedicine. 2019;14:6555–6574. doi:10.2147/IJN.S213613.
   PubMed Web of Science ®Google Scholar
• Vora B, Khopade AJ, Jain NK. Proniosome based transdermal delivery of levonorgestrel for effective contraception. J Control Release. 1998;54(2):149–165. doi:10.1016/s0168-3659(97)00100-4.
   PubMed Web of Science ®Google Scholar
• Ramkanth S, Chetty CM, Sudhakar Y, Thiruvengadarajan VS, Anitha P, Gopinath C. Development, characterization & invivo evaluation of proniosomal based transdermal delivery system of Atenolol. Future J Pharmaceut Sci. 2018;4(1):80–87. doi:10.1016/j.fjps.2017.10.003.
   Web of Science ®Google Scholar
• Soliman SM, Abdelmalak NS, El-Gazayerly ON, Abdelaziz N. Novel non-ionic surfactant proniosomes for transdermal delivery of lacidipine: optimization using 2(3) factorial design and in vivo evaluation in rabbits. Drug Deliv. 2016;23(5):1608–1622. doi:10.3109/10717544.2015.1132797.
   PubMed Web of Science ®Google Scholar
• Yasam VR, Jakki SL, Natarajan J, Venkatachalam S, Kuppusamy G, Sood S, Jain K. A novel vesicular transdermal delivery of nifedipine - preparation, characterization and in vitro/in-vivo evaluation. Drug Deliv. 2016;23(2):619–630. doi:10.3109/10717544.2014.931484.
   PubMed Web of Science ®Google Scholar
• Thi TTH, Suys EJA, Lee JS, Nguyen DH, Park KD, Truong NP. Lipid-based nanoparticles in the clinic and clinical trials: from cancer nanomedicine to COVID-19 vaccines. Vaccines (Basel). 2021;9(4):359. doi:10.3390/vaccines9040359.
   PubMed Web of Science ®Google Scholar
• Kumar G, Virmani T, Pathak K, Alhalmi A. A revolutionary blueprint for mitigation of hypertension via nanoemulsion. Biomed Res Int. 2022;2022:1–12.doi:10.1155/2022/4109874.
   Web of Science ®Google Scholar
• Varshosaz J, Andalib S, Tabbakhian M, Ebrahimzadeh N. Development of lecithin nanoemulsion based organogels for permeation enhancement of metoprolol through rat skin. J Nanomater. 2013;2013:1–10. doi:10.1155/2013/139437.
   Web of Science ®Google Scholar
• Rizwan M, Aqil M, Azeem A, Talegaonkar S, Sultana Y, Ali A. Enhanced transdermal delivery of carvedilol using nanoemulsion as a vehicle. J Exp Nanosci. 2010;5(5):390–411. doi:10.1080/17458080903583964.
   Web of Science ®Google Scholar
• Zaid Alkilani A, Hamed R, Al-Marabeh S, Kamal A, Abu-Huwaij R, Hamad I. Nanoemulsion-based film formulation for transdermal delivery of carvedilol. J Drug Delivery Sci Technol. 2018;46:122–128. doi:10.1016/j.jddst.2018.05.015.
   Web of Science ®Google Scholar
• Malgope A, Murthy PN, Ramani R, Dey S. Development of nanoemulsion as carrier for transdermal delivery of valsartan. Int J Pharm Chem Sci. 2013;2(4):1655–1665.
   Google Scholar
• Aqil M, Kamran M, Ahad A, Imam SS. Development of clove oil based nanoemulsion of olmesartan for transdermal delivery: box–Behnken design optimization and pharmacokinetic evaluation. J Mol Liq. 2016;214:238–248. doi:10.1016/j.molliq.2015.12.077.
   Web of Science ®Google Scholar
• Yadav SA, Poddar SS. In-vitro and in-vivo evaluation of nanoemulsion gel for transdermal drug delivery of nimodipine. Asian J Pharm Clin Res. 2015;8:119–124.
   Google Scholar
• Mariyate J, Bera A. A critical review on selection of microemulsions or nanoemulsions for enhanced oil recovery. J Mol Liq. 2022;353:118791. doi:10.1016/j.molliq.2022.118791.
   Google Scholar
• Rao J, McClements DJ. Food-grade microemulsions and nanoemulsions: role of oil phase composition on formation and stability. Food Hydrocolloids. 2012;29(2):326–334. doi:10.1016/j.foodhyd.2012.04.008.
   Web of Science ®Google Scholar
• Gannu R, Palem CR, Yamsani VV, Yamsani SK, Yamsani MR. Enhanced bioavailability of lacidipine via microemulsion based transdermal gels: formulation optimization, ex vivo and in vivo characterization. Int J Pharm. 2010;388(1-2):231–241. doi:10.1016/j.ijpharm.2009.12.050.
   PubMed Web of Science ®Google Scholar
• Souza de Araujo GR, Mendonça da Cruz Macieira G, Xavier de Oliveira D, Santos Matos S, Nery Dos Santos Q, Otubo L, Antunes de Souza Araújo A, Cavalcante Duarte M, Moreira Lira AA, de Souza Nunes R, et al. Microemulsions formed by PPG-5-CETETH-20 at low concentrations for transdermal delivery of nifedipine: structural and in vitro study. Colloids Surf B Biointerfaces. 2022;214:112474. doi:10.1016/j.colsurfb.2022.112474.
   PubMed Web of Science ®Google Scholar
• Wu P-C, Lin Y-H, Chang J-S, Huang Y-B, Tsai Y-H. The effect of component of microemulsion for transdermal delivery of nicardipine hydrochloride. Drug Dev Ind Pharm. 2010;36(12):1398–1403. doi:10.3109/03639045.2010.485277.
   PubMed Web of Science ®Google Scholar
• Oparil S, Weber M. Angiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: an emerging strategy in hypertension therapy. Postgrad Med. 2009;121(2):25–39. doi:10.3810/pgm.2009.03.1974.
   PubMed Web of Science ®Google Scholar
• Sood J, Sapra B, Tiwary AK. Microemulsion transdermal formulation for simultaneous delivery of valsartan and nifedipine: formulation by design. AAPS PharmSciTech. 2017;18(6):1901–1916. doi:10.1208/s12249-016-0658-0.
   PubMed Web of Science ®Google Scholar
• Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161–177.
   Google Scholar
• Müller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm. 2002;242(1-2):121–128. doi:10.1016/s0378-5173(02)00180-1.
   PubMed Web of Science ®Google Scholar
• Silva AC, Santos D, Ferreira DC, Souto EB. Minoxidil-loaded nanostructured lipid carriers (NLC): characterization and rheological behaviour of topical formulations. Pharmazie. 2009;64(3):177–182.
   PubMed Web of Science ®Google Scholar
• Kapoor H, Aqil M, Imam SS, Sultana Y, Ali A. Formulation of amlodipine nano lipid carrier: formulation design, physicochemical and transdermal absorption investigation. J Drug Delivery Sci Technol. 2019;49:209–218. doi:10.1016/j.jddst.2018.11.004.
   Web of Science ®Google Scholar
• Bhaskar K, Krishna Mohan C, Lingam M, Jagan Mohan S, Venkateswarlu V, Madhusudan Rao Y, Bhaskar K, Anbu J, Ravichandran V. Development of SLN and NLC enriched hydrogels for transdermal delivery of nitrendipine: in vitro and in vivo characteristics. Drug Dev Ind Pharm. 2009;35(1):98–113. doi:10.1080/03639040802192822.
   PubMed Web of Science ®Google Scholar
• Vyas SP, Murthy RSR, Narang RK. Nanocolloidal carriers: site specific and controlled drug delivery. CBS Publishers & Distributors Pvt Ltd, India; 2011.
   Google Scholar
• Gebicki JM, Hicks M. Ufasomes are stable particles surrounded by unsaturated fatty acid membranes. Nature. 1973;243(5404):232–234. doi:10.1038/243232a0.
   PubMed Web of Science ®Google Scholar
• Hargreaves WR, Deamer DW. Liposomes from ionic, single-chain amphiphiles. Biochemistry. 1978;17(18):3759–3768. doi:10.1021/bi00611a014.
   PubMed Web of Science ®Google Scholar
• Kumar L, Verma S, Kumar S, Prasad DN, Jain AK. Fatty acid vesicles acting as expanding horizon for transdermal delivery. Artif Cells Nanomed Biotechnol. 2017;45(2):251–260. doi:10.3109/21691401.2016.1146729.
   PubMed Web of Science ®Google Scholar
• Verma S, Bhardwaj A, Vij M, Bajpai P, Goutam N, Kumar L. Oleic acid vesicles: a new approach for topical delivery of antifungal agent. Artif Cells Nanomed Biotechnol. 2014;42(2):95–101. doi:10.3109/21691401.2013.794351.
   PubMed Web of Science ®Google Scholar
• Kumar L, Utreja P. Oleic acid vesicles for transdermal delivery of propranolol hydrochloride: development and characterization. Curr Drug Therapy. 2019;14:1–13.
   Google Scholar
• Kumar Gaur P, Mishra S, Purohit S. Nanovesicles of nitrendipine with lipid complex for transdermal delivery: pharmacokinetic and pharmacodynamic studies. Artif Cells Nanomed Biotechnol. 2016;44(7):1684–1693. doi:10.3109/21691401.2015.1080170.
   PubMed Web of Science ®Google Scholar
• Schwengber A, Prado HJ, Zilli DA, Bonelli PR, Cukierman AL. Carbon nanotubes buckypapers for potential transdermal drug delivery. Mater Sci Eng C Mater Biol Appl. 2015;57:7–13. doi:10.1016/j.msec.2015.07.030.
   PubMed Web of Science ®Google Scholar
• Zhang K, Zhuang Y, Li J, Liu X, He S. Poly(acrylic acid)-modified MoS(2) nanoparticle-based transdermal delivery of atenolol. Int J Nanomedicine. 2020;15:5517–5526. doi:10.2147/IJN.S257906.
   PubMed Web of Science ®Google Scholar
• Chen J, Cai B, Gu W, Xiao H, Li J. The prepartion method and application of percutaneous-absorption-promoting propranolol composite phospholipid transfersomes. Chinese Patent. CN102846546B, 2014.
   Google Scholar
• Cai Y, Zhou X, Mo D, He R, Li J, Zhang W. The preparation method and application of propranolol hydrochloride submicron emulsion gel. Chinese Patent. CN105434337B, 2019.
   Google Scholar
• Chen X, Yu J, Luo B, Li L, Cai B, Shao J, Wang B. A kind of self-assembled propranolol nanoparticulate drug and prepartion method thereof. Chinese Patent. CN116139274A, 2023.
   Google Scholar
• Pope E, Lara-Corrales I, Sibbald C, Liy-Wong C, Kanigsberg N, Drolet B, Ma J. Noninferiority and safety of nadolol vs propranolol in infants with infantile hemangioma: a randomized clinical trial. JAMA Pediatr. 2022;176(1):34–41. doi:10.1001/jamapediatrics.2021.4565.
   PubMed Web of Science ®Google Scholar
• Zeng L, Tao C, Liu Z, Zhang J, Zhang M, Zhang J, Fang S, Ma X, Song H, Zhou X, et al. Preparation and evaluation of cubic nanoparticles for improved transdermal delivery of propranolol hydrochloride. AAPS PharmSciTech. 2020;21(7):266. doi:10.1208/s12249-020-01809-7.
   PubMed Web of Science ®Google Scholar
• Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, Guibaud L, Baselga E, Posiunas G, Phillips RJ, Caceres H, Lopez Gutierrez JC, Ballona R, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015;372(8):735–746. doi:10.1056/NEJMoa1404710.
   PubMed Web of Science ®Google Scholar
• Jiang C, Ma R, Jiang X, Fang R, Ye J. A transfersomes hydrogel patch for cutaneous delivery of propranolol hydrochloride: formulation, in vitro, ex vivo and in vivo studies. J Liposome Res. 2023;33(3):258–267. doi:10.1080/08982104.2022.2162539.
   PubMed Web of Science ®Google Scholar
• Ferrario CM, VonCannon JL, Zhang J, Figueroa JP, Wright KN, Groban L, Saha A, Meredith JW, Ahmad S. Immunoneutralization of human angiotensin-(1-12) with a monoclonal antibody in a humanized model of hypertension. Peptides. 2022;149:170714. doi:10.1016/j.peptides.2021.170714.
   PubMed Web of Science ®Google Scholar
• Bairwa M, Pilania M, Gupta V, Yadav K. Hypertension vaccine may be a boon to millions in developing world. Hum Vaccin Immunother. 2014;10(3):708–713. doi:10.4161/hv.27520.
   PubMed Web of Science ®Google Scholar
• Desai AS, Webb DJ, Taubel J, Casey S, Cheng Y, Robbie GJ, Foster D, Huang SA, Rhyee S, Sweetser MT, et al. 2023. Zilebesiran, an RNA interference therapeutic agent for hypertension. N Engl J Med. 2023;389(3):228–238. doi:10.1056/NEJMoa2208391.
   PubMed Web of Science ®Google Scholar